October 13, 2020
3 min watch
Save
VIDEO: Tremfya produces clinical, endoscopic response in Crohn’s disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this exclusive video, William J. Sandborn, MD, from the University of California, San Diego, discusses interim results from the phase 2 GALAXI 1 study of Tremfya in patients with Crohn’s disease.
In the study, researchers explored the efficacy and safety of three different doses of the drug (guselkumab, Janssen) against placebo, as well as a reference comparator, Stelara (ustekinumab, Janssen).
All three doses induced greater improvements in clinical and endoscopic outcomes compared with placebo, according to Sandborn.
Published by:
Sources/Disclosures
Collapse
Source:
Sandborn WJ, et al. Abstract OP089. Presented at: UEG Week Virtual. Oct. 11-13, 2020.
Disclosures:
The study was supported by Janssen Research & Development.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.